Pharmaceutical firm Gland Pharma will be investing Rs 400 crore to create additional capabilities in its existing facility at Genome Valley in Telangana. The announcement was made during a meeting attended by Telangana Industries Minister KT Rama Rao and the officials of Gland Pharma.

The project investment is estimated to be about Rs 400 crore, wherein the expanded facility will have an employment generation potential of more than 500 in the qualified, skilled and semi-skilled category and the requisite workforce will be sourced from nearby places.

The facility will be upgraded to adhere to national and international regulations in the manufacturing of the biological products, which will see the implementation of GMP guidelines for the respective product lines.

The Rs 300 crore biopharmaceutical facility was set up in February 2022 at Genome Valley to manufacture biologicals, biosimilar, antibodies and recombinant insulin.

The expansion initiative of the company’s (contract development and manufacturing organization) bio-CDMO facilities in Shamirpet, Telangana will bolster the vision of Telangana government to position the state a hub for global pharmaceutical requirements.